Navigation Links
Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
Date:7/20/2009

NEW YORK, July 20 /PRNewswire/ -- Double Helix Consulting US, a division of London-based Double Helix Development group, today announced the appointment of Caryn Zieses to the position of Senior Consultant. Zieses joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry, which provides product commercialization services to firms in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:

  • Product value message development and testing
  • Commercial assessment
  • Development program and clinical trial planning
  • Managed markets strategy
  • Pharmacoeconomic evaluation and health technology assessment
  • Payer and provider insight evaluation and influence planning
  • Pricing and reimbursement strategy, negotiation simulation, and training

Drew Baker, President of Double Helix Consulting US, commented, "Caryn complements our international market access, pricing and reimbursement capabilities through her vast experience in planning and implementing product development and launch strategies for the US market. Her intimate knowledge of managed care market structure, formulary management, contracting strategies, and marketing communications strengthens Double Helix's ability to meet our clients' commercial objectives in the increasingly cost-conscious and value-driven US market."

Chief Executive Officer of Double Helix Development Group, Dr. Wayne Phillips, added, "Double Helix Consulting offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from both the client and consulting sides. As an example, our growing emerging markets practice provides clients with the intelligence to implement successful strategies in the world's largest and most rapidly developing economies. Caryn's experience in product planning and launch strategy bolsters our expanding capabilities."

Zieses joins the Double Helix Consulting US team from the Pricing & Reimbursement consulting practice of IMS Health. She has worked closely with both large and small pharmaceutical and biotech clients to deliver global strategic recommendations that would inform decisions related to drug pricing, market access, clinical trial design, value messaging, payer attitudes, forecasting, and commercial assessments. Her expertise in US payer trends spans both public and private organizations and the policy changes they continually face. She has extensive experience in a diverse set of therapy areas, in particular those related to neurosciences, pulmonology, immunology and ophthalmology. She also has four years of previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an MEM from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania.

http://www.doublehelixdevelopment.com

(Photo: http://www.newscom.com/cgi-bin/prnh/20090720/NY49139 )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090330/NY91277LOGO )


'/>"/>
SOURCE Double Helix Consulting US
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products
2. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
3. Nanoparticles double their chances of getting into sticky situations
4. Carbon nanotube avalanche process nearly doubles current
5. SleepQuest Compliance Again Doubles Industry Average
6. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
7. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
8. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
9. Method sorts out double-walled carbon nanotube problem
10. Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year
11. US Neuropathic Pain Market Value Doubles to $5 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)...  Personal Genome Diagnostics Inc. (PGDx) today announced ... the U.S. Department of Veterans Affairs (VA) that ... company,s new CancerSELECT ™ 125 test. CancerSELECT ... test that includes microsatellite instability status (MSI), a ... checkpoint inhibitor immunotherapies. CancerSELECT 125 will be available ...
(Date:3/20/2017)... CA (PRWEB) , ... March ... ... are substances that interfere with the ability of endogenous hormones to regulate ... inhibiting ligand binding activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and ...
(Date:3/20/2017)... ... March 20, 2017 , ... Charm Sciences, ... & play system that counts Peel Plate microbial test colonies, stores plate images, ... stand-alone unit has an internal computer, and is accurate within 10% of an ...
(Date:3/20/2017)... , March 20, 2017 Western Institutional Review ... ethical review of clinical research, announced today the launch ... (SRS) for NIH-funded multi-site research. As the ... institution clients, WIRB has an extensive background in reviewing ... status as the IRB of record for the majority ...
Breaking Biology Technology:
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):